Blake Borgeson Sells 11,447 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 11,447 shares of the stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $6.72, for a total value of $76,923.84. Following the transaction, the director now directly owns 7,077,560 shares in the company, valued at approximately $47,561,203.20. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, October 15th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.67, for a total value of $76,351.49.
• On Tuesday, October 1st, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.22, for a total value of $71,200.34.
• On Tuesday, September 17th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $6.84, for a total value of $78,297.48.
• On Tuesday, September 3rd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.27, for a total value of $71,772.69.
• On Tuesday, August 20th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.12, for a total value of $81,502.64.
• On Tuesday, August 6th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $6.82, for a total value of $78,068.54.

Recursion Pharmaceuticals Stock Up 1.3 %

Shares of NASDAQ:RXRX opened at $6.40 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.07 and a current ratio of 6.07. Recursion Pharmaceuticals, Inc. has a 52-week low of $5.03 and a 52-week high of $15.74. The company has a market capitalization of $1.80 billion, a PE ratio of -3.95 and a beta of 0.80. The company has a fifty day moving average of $6.63 and a 200-day moving average of $7.64.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The company had revenue of $14.42 million for the quarter, compared to the consensus estimate of $11.96 million. During the same period last year, the company earned ($0.38) EPS. Recursion Pharmaceuticals’s revenue for the quarter was up 30.9% compared to the same quarter last year. On average, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on RXRX. Needham & Company LLC cut their price target on Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, September 4th. Jefferies Financial Group dropped their price target on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a report on Tuesday, September 3rd. KeyCorp decreased their price objective on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Finally, Leerink Partners decreased their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research report on Tuesday, September 3rd. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $9.40.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Privium Fund Management B.V. boosted its holdings in Recursion Pharmaceuticals by 50.0% in the 3rd quarter. Privium Fund Management B.V. now owns 78,000 shares of the company’s stock valued at $514,000 after purchasing an additional 26,000 shares during the period. ARK Investment Management LLC raised its position in Recursion Pharmaceuticals by 16.4% in the 3rd quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company’s stock worth $215,949,000 after purchasing an additional 4,626,268 shares during the period. QRG Capital Management Inc. purchased a new position in shares of Recursion Pharmaceuticals in the third quarter valued at about $120,000. Clear Creek Financial Management LLC purchased a new position in shares of Recursion Pharmaceuticals in the third quarter valued at about $81,000. Finally, Chicago Partners Investment Group LLC purchased a new position in shares of Recursion Pharmaceuticals in the third quarter valued at about $101,000. 89.06% of the stock is owned by institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.